USSTOCK.TODAY
Regular Market
Log in Sign up

Rigel Pharmaceuticals Records $72.3 Million in Net Product Sales for Q3 2026

The Motley Fool +1 · ·by G4L

RIGL
RIGL Rigel Pharmaceuticals
$43.91 +4.42%
View chart & analysis →
  1. 1Rigel Pharmaceuticals recorded a 13% increase in net product sales in Q3 2026 compared to Q3 2025.
  2. 2Vepanu was launched in the US market on August 13 and generated $6.6 million in net product sales during the third quarter.
  3. 3Rigel Pharmaceuticals achieved a 17% increase in net product sales in 2026 year-to-date compared to the same period in 2025.

So what's the key point?

Rigel Pharmaceuticals' product sales grew by 13 percent compared to the same period last year. The newly released Vepanu helped increase sales after entering the market.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Riesel Pharmaceuticals eyes Vepinu launch performance ahead of Q3 earnings Earnings Whispers · Oct 30Phio Pharmaceuticals Corp. Announces PH-762 Program Progress and Third Quarter Financial Results Newsfile Corp. +3 · 5d agoOscar Health reports Q3 earnings beating estimates and raises annual guidance Earnings Whispers +2 · 5d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news